Andrew J. Beavil

Apr 25, 2023 | nature.com | Tony Cheung |Chara Stavraka |Giulia Pellizzari |Francis Man |Hannah Gould |Andrew J. Beavil | +4 more

AbstractOutcomes for half of patients with melanoma remain poor despite standard-of-care checkpoint inhibitor therapies. The prevalence of the melanoma-associated antigen chondroitin sulfate proteoglycan 4 (CSPG4) expression is ~70%, therefore effective immunotherapies directed at CSPG4 could benefit many patients. Since IgE exerts potent immune-activating functions in tissues, we engineer a monoclonal IgE antibody with human constant domains recognizing CSPG4 to target melanoma.